Investment highlights

  • Focus on developing a novel treatment for inflammatory and autoimmune diseases targeting the melanocortin system

  • Several near-term value inflection points from Phase II development and other corporate activities

  • First-in-class compound with unique biology and once-daily dosing designed to have versatility across several indications

  • Fortified IP portfolio providing protection until 2042

  • Experienced management team and BoD with strong track record in drug development and deal making

  • Continually evaluating compelling business development opportunities